The contribution of deleterious DPYD gene sequence variants to Xuoropyrimidine toxicity in British cancer patients (original) (raw)
The contribution of deleterious DPYD gene sequence variants to fluoropyrimidine toxicity in British cancer patients
Paul Ross
Cancer Chemotherapy and Pharmacology, 2010
View PDFchevron_right
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant
MARIA IOLE NATALICCHIO
Medicine, 2019
View PDFchevron_right
Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature
Hamoud Al-Khallaf
Clinics and Practice, 2021
View PDFchevron_right
Severe fluoropyrimidine-related toxicity: clinical implications of DPYD analysis and UH2/U ratio evaluation
Elisa Giorgio
Cancer Chemotherapy and Pharmacology, 2011
View PDFchevron_right
Integrating rare genetic variants into DPYD pharmacogenetic testing may help preventing fluoropyrimidine-induced toxicity
Meyling Cheok
Research Square (Research Square), 2023
View PDFchevron_right
Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule
Adriana Albini
Internal and Emergency Medicine, 2013
View PDFchevron_right
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
Ramon Colomer
Clinical and Translational Oncology
View PDFchevron_right
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
Marzia Del Re
The EPMA Journal, 2010
View PDFchevron_right
Strong Association of a Common Dihydropyrimidine Dehydrogenase Gene Polymorphism with Fluoropyrimidine-Related Toxicity in Cancer Patients
Marion Kiechle
PLoS ONE, 2008
View PDFchevron_right
Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase
Ilaria Bossi, Emilio Clementi, Stefania Cheli, Felicia Falvella
International journal of molecular sciences, 2015
View PDFchevron_right
New DPYD variants causing DPD deficiency in patients treated with fluoropyrimidine
Luis Robles
Cancer Chemotherapy and Pharmacology, 2020
View PDFchevron_right
A DPYD variant (Y186C) specific to individuals of African descent in a patient with life-threatening 5-FU toxic effects: potential for an individualized medicine approach
Adam Lee
Mayo Clinic proceedings, 2014
View PDFchevron_right
The Prevalence of DPYD*9A (c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis
Girijesh Kumar Patel
Clinical Colorectal Cancer, 2019
View PDFchevron_right
Fluoropyrimidine-Associated Toxicity in Two Gastrointestinal Cancer Patients: Potential Role of Common DPYD Polymorphisms
Felicia Falvella
Chemotherapy, 2017
View PDFchevron_right
Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene
Charlotta Enerbäck
Clinical Biochemistry, 2010
View PDFchevron_right
New advances in DPYD genotype and risk of severe toxicity under capecitabine
Jean-marc Ferrero
PloS one, 2017
View PDFchevron_right
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene–drug interaction of DPYD and fluoropyrimidines
Gerard Rongen
European Journal of Human Genetics, 2019
View PDFchevron_right
Implementation of pharmacogenetic testing in oncology: DPYD-guided dosing to prevent fluoropyrimidine toxicity in British Columbia
Sean Young
Frontiers in Pharmacology
View PDFchevron_right
The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy. An Italian case-control study
Lorenzo Tofani
British Journal of Cancer
View PDFchevron_right
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
Martina Cornel
Frontiers in Pharmacology
View PDFchevron_right
Germline pharmacogenomics of DPYD*9A (c.85T>C) variant in patients with gastrointestinal malignancies treated with fluoropyrimidines
Moh'd Khushman
View PDFchevron_right
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
Annemieke Cats
Journal of Clinical Oncology, 2015
View PDFchevron_right
Revisiting the Clinical Importance of DPYD*9A (c.85T>C) Variant of Dihydropyrimidine Dehydrogenase (DPYD) Gene in Patients Treated with Fluoropyrimidine-Based Chemotherapy
Girijesh Kumar Patel
Journal of Molecular Biomarkers & Diagnosis
View PDFchevron_right
Predicting Dihydropyrimidine Dehydrogenase Deficiency and Related 5-Fluorouracil Toxicity: Opportunities and Challenges of DPYD Exon Sequencing and the Role of Phenotyping Assays
Ottavia De Luca
International Journal of Molecular Sciences
View PDFchevron_right
Investigation of IVS14 + 1G > A polymorphism of DPYD gene in a group of Bosnian patients treated with 5-Fluorouracil and capecitabine
Timur Ceric
Bosnian journal of basic medical sciences / Udruženje basičnih mediciniskih znanosti = Association of Basic Medical Sciences, 2010
View PDFchevron_right
Routine Dihydropyrimidine Dehydrogenase Testing for Anticipating 5-Fluorouracil–Related Severe Toxicities: Hype or Hope?
Cedric Mercier
Clinical Colorectal Cancer, 2010
View PDFchevron_right
SNPs and Haplotypes in DPYD and Outcome of Capecitabine-Response
Annemieke Cats
Clinical Cancer Research, 2011
View PDFchevron_right
Analysis of the DPYD Gene Implicated in 5-Fluorouracil Catabolism in a Cohort of Caucasian Individuals
Marion Kiechle, Manfred Schmitt
Clinical Cancer Research, 2005
View PDFchevron_right
Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update
Kelly Birdwell
Clinical Pharmacology & Therapeutics, 2014
View PDFchevron_right